.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The primary results of the DELTA-HF trial demonstrate that the eLym System heart failure therapy provides a safe and effective method for interstitial decongestion. Managing fluid overload is often difficult in patients with acute decompensated heart failure (ADHF). Consequently, persistent congestion remains a significant risk factor for rehospitalization. However, this innovative endovenous axial pump targets the lymphatic system directly to enhance fluid removal.
The system facilitates drainage by creating a localized reduced-pressure zone at the venous angle. Specifically, the device utilizes an endovenous pump to lower pressure where the thoracic duct connects to the venous system. Furthermore, this mechanism supports the natural drainage of interstitial fluid back into the circulation. This approach differs from standard diuretics, which primarily target intravascular volume.
Notably, the trial achieved successful device deployment in all 40 participants. During the therapy period, patients lost an average of 3.6 kg. Furthermore, weight loss increased to 6.8 kg by the time of hospital discharge. Additionally, the median modified EVEREST Clinical Congestion Score improved significantly from 5.0 at baseline to 0.0 at discharge. Most importantly, kidney function remained stable throughout the treatment process.
Moreover, the study reported a low 90-day heart failure rehospitalization rate of only 9.5%. This finding is particularly encouraging compared to standard care. Consequently, the eLym system represents a promising adjunctive therapy for refractory congestion. Researchers look forward to further large-scale randomized controlled trials to confirm these benefits.
The system creates a low-pressure zone at the thoracic duct junction. This helps the lymphatic system move excess fluid from tissues into the bloodstream for excretion.
No, the DELTA-HF trial results showed that kidney function remained stable during and after the treatment. Creatinine levels and GFR did not change significantly.
In the trial, the mean therapy time was approximately 23.1 hours. Clinicians successfully deployed the device in every case with minimal complications.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Professional judgment should be exercised. Refer to the latest local and national guidelines for clinical practice.
References
Nuche J et al. Safety and Feasibility of the eLymTM System for Interstitial Decongestion in Acute Decompensated Heart Failure: Primary results of the DELTA-HF trial. Eur J Heart Fail. 2026 May 10. doi: undefined. PMID: 42106950.
Biegus J, et al. Design and Rationale of the eLym™ System for Decongestion of Excess Lymphatic Fluid via the Thoracic Duct in Acute Heart Failure (DELTA-HF). ESC Heart Fail. 2024 Dec 24. doi: 10.1002/ehf2.15192.
WhiteSwell. WhiteSwell Announces New Data Supporting Acute Decompensated Heart Failure Treatment with eLym System. THT Meeting 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The DELTA-HF trial demonstrates the safety and efficacy of the eLym System in promoting lymphatic drainage and decongestion in heart failure patients....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
